METABOLIC & WEIGHT RESEARCH / FAQ
Questions From the Trial Record
Direct, citation-anchored answers to the questions readers most often bring to these four metabolic research peptides.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide modeled on residues 177-191 of human growth hormone, with an added N-terminal tyrosine. It was developed as an oral anti-obesity drug candidate on the premise that this fragment carries growth hormone's fat-metabolizing activity without engaging the growth hormone receptor itself. It is not FDA-, EMA-, or TGA-approved for any indication; its anti-obesity development program was discontinued after the pivotal human trial did not demonstrate statistically significant weight loss over placebo [3].
Does AOD-9604 actually work?
The honest answer is mixed and depends on which endpoint is being asked about. In rodent models, AOD-9604 clearly reduced body fat and increased fat oxidation through beta-3 adrenergic receptor up-regulation [4][5]. In roughly six human trials totaling about 900 obese adults, it was safe and well tolerated, essentially indistinguishable from placebo on side effects [3], but the trials measuring actual weight loss did not clear the bar for statistical significance, and the program was discontinued. In short: it worked in mice, it was safe in people, but it did not demonstrate a weight-loss benefit in people.
How does AOD-9604 work?
In animal models, AOD-9604 inhibits an enzyme involved in fat synthesis, acetyl-CoA carboxylase, and promotes fat burning by increasing beta-3 adrenergic receptor expression in fat tissue [4]. Critically, it does not bind the growth hormone receptor, which is the entire design rationale — the goal was to isolate growth hormone's fat-metabolism signal from its growth-promoting and blood-sugar effects. A knockout-mouse study found that mice without a functional beta-3 adrenergic receptor lost the chronic weight-loss response to AOD-9604 entirely, while a short-term boost in energy expenditure was preserved regardless [4][5].
What does retatrutide do?
Retatrutide activates three receptors at once: GLP-1, GIP, and glucagon. The GLP-1 and GIP arms reduce appetite and improve glucose-dependent insulin release; the glucagon arm is thought to raise energy expenditure through fat-tissue thermogenesis. In its pivotal Phase 2 obesity trial, 12 mg once weekly produced a mean -24.2% body-weight change over 48 weeks versus -2.1% with placebo, the largest Phase 2 weight-loss figure reported for any incretin-class compound to date [9]. It is investigational and not approved by any regulator.
How does retatrutide work?
Retatrutide layers a third receptor, glucagon, on top of the GLP-1/GIP mechanism that single- and dual-agonist compounds use. GLP-1 and GIP receptor activation suppresses appetite and boosts glucose-dependent insulin secretion; glucagon receptor activation, unusually, appears to increase energy expenditure through brown-fat thermogenesis and fatty-acid oxidation rather than raising blood glucose in this combined context [6]. Cryo-EM structural work confirms it engages all three receptors with distinct binding geometry at each, and post-hoc metabolic profiling shows higher doses reduce triglycerides and shift insulin-resistance biomarkers in a favorable direction [7][12].
Is retatrutide FDA approved?
No. Retatrutide is not approved by the FDA or any other regulator as of mid-2026. It remains in Phase 3 clinical trials, the TRIUMPH program; all efficacy and safety figures currently available come from Phase 1 and Phase 2 studies [9][10][11]. The FDA issued dozens of warning letters to vendors selling unauthorized research-grade retatrutide in 2025. It is legally available only to participants in registered clinical trials.
What is semaglutide?
Semaglutide is a synthetic peptide that activates the GLP-1 receptor, mimicking a natural gut hormone released after eating. It is FDA-approved for type 2 diabetes, chronic weight management, reducing cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and, since 2025, a liver condition called MASH. It is available as a once-weekly subcutaneous injection and a once-daily oral tablet [16][17]. It is a prescription medicine, not a research-only compound.
What is semaglutide used for?
FDA-approved uses include lowering blood glucose in type 2 diabetes, reducing body weight in chronic weight management at the higher weekly dose, reducing major cardiovascular events in adults with established cardiovascular disease and overweight or obesity, and treating MASH. In research, it has also reduced the risk of major kidney-disease events by 24% in a dedicated trial in type 2 diabetes with chronic kidney disease [14][15].
How does semaglutide work for weight loss?
Semaglutide's weight effect is mostly central, meaning it acts through the brain rather than the gut alone. It crosses into hypothalamic and brainstem appetite circuits, activating neurons that signal fullness and suppressing neurons that drive hunger, which reduces both food intake and the background mental preoccupation with food some people describe as food noise. It also slows gastric emptying, extending the sensation of fullness after a meal. In its pivotal weight-management trial, this translated into a mean -14.9% body-weight change at 68 weeks versus -2.4% with placebo [16].
What is tesamorelin?
Tesamorelin is a synthetic 44-amino-acid analogue of growth hormone-releasing hormone, chemically modified to resist rapid enzymatic breakdown. It is FDA-approved to reduce excess visceral, abdominal, fat in HIV-infected adults with antiretroviral-associated lipodystrophy, a narrow, specific indication, not a general weight-loss approval [19].
What does tesamorelin do?
Tesamorelin stimulates the pituitary gland to release more of the body's own growth hormone, which in turn raises IGF-1 and promotes fat breakdown with a preference for visceral fat. A 2026 meta-analysis of five randomized trials found it reduced visceral fat by a mean of about 27.7 cm2 and increased lean body mass by about 1.4 kg, without serious adverse events [18]. Its effect requires continued dosing; visceral fat reaccumulates once treatment stops [22].
Will tesamorelin help me lose belly fat?
This site does not answer that as a personal recommendation — that is a question for a licensed clinician evaluating an individual's specific situation. What the published research shows is narrower and more specific than belly fat in general: tesamorelin's trial evidence is in HIV-associated lipodystrophy, where it reduced visceral adipose tissue by roughly 28 cm2 across pooled trials [18] and by 42 cm2 in a dedicated randomized trial [20], while sustaining an 18% reduction through 52 weeks in a long-term program [22]. It is not approved for general abdominal-fat reduction outside that condition, and the studied benefit does not persist once dosing stops.